GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » 14-Day RSI

IDXG (Interpace Biosciences) 14-Day RSI : 60.63 (As of Dec. 13, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-13), Interpace Biosciences's 14-Day RSI is 60.63.

The industry rank for Interpace Biosciences's 14-Day RSI or its related term are showing as below:

IDXG's 14-Day RSI is ranked worse than
83.4% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.06 vs IDXG: 60.63

Competitive Comparison of Interpace Biosciences's 14-Day RSI

For the Diagnostics & Research subindustry, Interpace Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's 14-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's 14-Day RSI falls into.



Interpace Biosciences  (OTCPK:IDXG) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Interpace Biosciences  (OTCPK:IDXG) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Interpace Biosciences 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences Business Description

Traded in Other Exchanges
Address
2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054